KRYSTAL BIOTECH INC (KRYS) Stock Fundamental Analysis

NASDAQ:KRYS • US5011471027

276.45 USD
+6.19 (+2.29%)
At close: Feb 13, 2026
281.97 USD
+5.52 (+2%)
After Hours: 2/13/2026, 8:21:07 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

KRYS gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. While KRYS has a great health rating, its profitability is only average at the moment. KRYS scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings could make KRYS a good candidate for value investing.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • KRYS had positive earnings in the past year.
  • KRYS had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: KRYS reported negative net income in multiple years.
  • In the past 5 years KRYS reported 4 times negative operating cash flow.
KRYS Yearly Net Income VS EBIT VS OCF VS FCFKRYS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M -150M

1.2 Ratios

  • The Return On Assets of KRYS (16.04%) is better than 95.79% of its industry peers.
  • KRYS's Return On Equity of 17.48% is amongst the best of the industry. KRYS outperforms 95.03% of its industry peers.
  • The Return On Invested Capital of KRYS (12.28%) is better than 95.03% of its industry peers.
Industry RankSector Rank
ROA 16.04%
ROE 17.48%
ROIC 12.28%
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
KRYS Yearly ROA, ROE, ROICKRYS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

  • The Profit Margin of KRYS (53.30%) is better than 98.47% of its industry peers.
  • Looking at the Operating Margin, with a value of 42.40%, KRYS belongs to the top of the industry, outperforming 99.24% of the companies in the same industry.
  • With an excellent Gross Margin value of 94.26%, KRYS belongs to the best of the industry, outperforming 94.65% of the companies in the same industry.
Industry RankSector Rank
OM 42.4%
PM (TTM) 53.3%
GM 94.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KRYS Yearly Profit, Operating, Gross MarginsKRYS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), KRYS is creating some value.
  • KRYS has more shares outstanding than it did 1 year ago.
  • KRYS has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KRYS Yearly Shares OutstandingKRYS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
KRYS Yearly Total Debt VS Total AssetsKRYS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • KRYS has an Altman-Z score of 47.50. This indicates that KRYS is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 47.50, KRYS belongs to the best of the industry, outperforming 96.37% of the companies in the same industry.
  • KRYS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 47.5
ROIC/WACC1
WACC12.25%
KRYS Yearly LT Debt VS Equity VS FCFKRYS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

  • KRYS has a Current Ratio of 10.14. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
  • KRYS has a better Current ratio (10.14) than 81.45% of its industry peers.
  • A Quick Ratio of 9.73 indicates that KRYS has no problem at all paying its short term obligations.
  • The Quick ratio of KRYS (9.73) is better than 80.69% of its industry peers.
Industry RankSector Rank
Current Ratio 10.14
Quick Ratio 9.73
KRYS Yearly Current Assets VS Current LiabilitesKRYS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 276.84% over the past year.
  • Looking at the last year, KRYS shows a very strong growth in Revenue. The Revenue has grown by 54.51%.
EPS 1Y (TTM)276.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%192.31%
Revenue 1Y (TTM)54.51%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.65%

3.2 Future

  • The Earnings Per Share is expected to grow by 58.10% on average over the next years. This is a very strong growth
  • KRYS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.67% yearly.
EPS Next Y123.14%
EPS Next 2Y66.89%
EPS Next 3Y50.55%
EPS Next 5Y58.1%
Revenue Next Year33.78%
Revenue Next 2Y37.6%
Revenue Next 3Y36.58%
Revenue Next 5Y31.67%

3.3 Evolution

KRYS Yearly Revenue VS EstimatesKRYS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
KRYS Yearly EPS VS EstimatesKRYS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 15

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 41.45, which means the current valuation is very expensive for KRYS.
  • Based on the Price/Earnings ratio, KRYS is valued cheaply inside the industry as 91.59% of the companies are valued more expensively.
  • KRYS's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 27.97.
  • The Price/Forward Earnings ratio is 33.19, which means the current valuation is very expensive for KRYS.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of KRYS indicates a rather cheap valuation: KRYS is cheaper than 91.40% of the companies listed in the same industry.
  • KRYS's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.96.
Industry RankSector Rank
PE 41.45
Fwd PE 33.19
KRYS Price Earnings VS Forward Price EarningsKRYS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, KRYS is valued cheaper than 91.40% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, KRYS is valued cheaply inside the industry as 92.35% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 48.42
EV/EBITDA 41.47
KRYS Per share dataKRYS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • KRYS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of KRYS may justify a higher PE ratio.
  • A more expensive valuation may be justified as KRYS's earnings are expected to grow with 50.55% in the coming years.
PEG (NY)0.34
PEG (5Y)N/A
EPS Next 2Y66.89%
EPS Next 3Y50.55%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for KRYS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KRYSTAL BIOTECH INC

NASDAQ:KRYS (2/13/2026, 8:21:07 PM)

After market: 281.97 +5.52 (+2%)

276.45

+6.19 (+2.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03
Earnings (Next)02-17
Inst Owners96.44%
Inst Owner Change-1.74%
Ins Owners11.65%
Ins Owner Change-1.32%
Market Cap8.02B
Revenue(TTM)373.16M
Net Income(TTM)198.91M
Analysts86.67
Price Target296.64 (7.3%)
Short Float %10.74%
Short Ratio8.98
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)76.19%
Min EPS beat(2)12.14%
Max EPS beat(2)140.23%
EPS beat(4)3
Avg EPS beat(4)41.54%
Min EPS beat(4)-13.89%
Max EPS beat(4)140.23%
EPS beat(8)4
Avg EPS beat(8)30.53%
EPS beat(12)5
Avg EPS beat(12)2.39%
EPS beat(16)7
Avg EPS beat(16)0.53%
Revenue beat(2)2
Avg Revenue beat(2)2.66%
Min Revenue beat(2)2.42%
Max Revenue beat(2)2.89%
Revenue beat(4)2
Avg Revenue beat(4)-1.53%
Min Revenue beat(4)-10.17%
Max Revenue beat(4)2.89%
Revenue beat(8)4
Avg Revenue beat(8)4.55%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)30.73%
PT rev (3m)34.87%
EPS NQ rev (1m)10.64%
EPS NQ rev (3m)12.7%
EPS NY rev (1m)6.79%
EPS NY rev (3m)30.98%
Revenue NQ rev (1m)0.02%
Revenue NQ rev (3m)-0.56%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)1.34%
Valuation
Industry RankSector Rank
PE 41.45
Fwd PE 33.19
P/S 21.48
P/FCF 48.42
P/OCF 45.5
P/B 7.05
P/tB 7.05
EV/EBITDA 41.47
EPS(TTM)6.67
EY2.41%
EPS(NY)8.33
Fwd EY3.01%
FCF(TTM)5.71
FCFY2.07%
OCF(TTM)6.08
OCFY2.2%
SpS12.87
BVpS39.24
TBVpS39.24
PEG (NY)0.34
PEG (5Y)N/A
Graham Number76.74
Profitability
Industry RankSector Rank
ROA 16.04%
ROE 17.48%
ROCE 13.77%
ROIC 12.28%
ROICexc 33.76%
ROICexgc 33.76%
OM 42.4%
PM (TTM) 53.3%
GM 94.26%
FCFM 44.37%
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 213.54%
Cap/Sales 2.84%
Interest Coverage 250
Cash Conversion 107.96%
Profit Quality 83.25%
Current Ratio 10.14
Quick Ratio 9.73
Altman-Z 47.5
F-Score7
WACC12.25%
ROIC/WACC1
Cap/Depr(3y)537.2%
Cap/Depr(5y)976.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)276.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%192.31%
EPS Next Y123.14%
EPS Next 2Y66.89%
EPS Next 3Y50.55%
EPS Next 5Y58.1%
Revenue 1Y (TTM)54.51%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.65%
Revenue Next Year33.78%
Revenue Next 2Y37.6%
Revenue Next 3Y36.58%
Revenue Next 5Y31.67%
EBIT growth 1Y143.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year182.48%
EBIT Next 3Y83.71%
EBIT Next 5YN/A
FCF growth 1Y239.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y269.59%
OCF growth 3YN/A
OCF growth 5YN/A

KRYSTAL BIOTECH INC / KRYS FAQ

Can you provide the ChartMill fundamental rating for KRYSTAL BIOTECH INC?

ChartMill assigns a fundamental rating of 6 / 10 to KRYS.


What is the valuation status for KRYS stock?

ChartMill assigns a valuation rating of 7 / 10 to KRYSTAL BIOTECH INC (KRYS). This can be considered as Undervalued.


What is the profitability of KRYS stock?

KRYSTAL BIOTECH INC (KRYS) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for KRYS stock?

The Price/Earnings (PE) ratio for KRYSTAL BIOTECH INC (KRYS) is 41.45 and the Price/Book (PB) ratio is 7.05.


What is the financial health of KRYSTAL BIOTECH INC (KRYS) stock?

The financial health rating of KRYSTAL BIOTECH INC (KRYS) is 8 / 10.